dc.contributor.author |
Anderson, Ronald
|
|
dc.contributor.author |
Rapoport, Bernardo Leon
|
|
dc.date.accessioned |
2018-05-25T12:07:27Z |
|
dc.date.available |
2018-05-25T12:07:27Z |
|
dc.date.issued |
2018-03-22 |
|
dc.description.abstract |
Realization of the full potential of immune checkpoint inhibitor-targeted oncoimmunotherapy
is largely dependent on overcoming the obstacles presented by the
resistance of some cancers, as well as on reducing the high frequency of immune-related
adverse events (IRAEs) associated with this type of immunotherapy. With the exception
of combining therapeutic monoclonal antibodies, which target different types of immune
checkpoint inhibitory molecules, progress in respect of improving therapeutic efficacy has
been somewhat limited to date. Likewise, the identification of strategies to predict and
monitor the development of IRAEs has also met with limited success due, at least in part,
to lack of insight into mechanisms of immunopathogenesis. Accordingly, considerable
effort is currently being devoted to the identification and evaluation of strategies which
address both of these concerns and it is these issues which represent the major focus of
the current review, particularly those which may be predictive of development of IRAEs.
Following an introductory section, this review briefly covers those immune checkpoint
inhibitors currently approved for clinical application, as well as more recently identified
immune checkpoint inhibitory molecules, which may serve as future therapeutic targets.
The remaining and more extensive sections represent overviews of: (i) putative strategies
which may improve the therapeutic efficacy of immune checkpoint inhibitors; (ii) recent
insights into the immunopathogenesis of IRAEs, most prominently enterocolitis; and
(iii) strategies, mostly unexplored, which may be predictive of development of IRAEs. |
en_ZA |
dc.description.department |
Immunology |
en_ZA |
dc.description.librarian |
am2018 |
en_ZA |
dc.description.uri |
http://www.frontiersin.org/Oncology |
en_ZA |
dc.identifier.citation |
Anderson R and Rapoport BL (2018)
Immune Dysregulation in Cancer
Patients Undergoing Immune
Checkpoint Inhibitor Treatment and
Potential Predictive Strategies for
Future Clinical Practice.
Front. Oncol. 8:80.
DOI: 10.3389/fonc.2018.00080. |
en_ZA |
dc.identifier.issn |
2234-943X (online) |
|
dc.identifier.other |
10.3389/fonc.2018.00080 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/65026 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Frontiers Media |
en_ZA |
dc.rights |
© 2018 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). |
en_ZA |
dc.subject |
Iomarkers |
en_ZA |
dc.subject |
CTLA-4 |
en_ZA |
dc.subject |
Enterocolitis |
en_ZA |
dc.subject |
Interleukin-17 |
en_ZA |
dc.subject |
Monoclonal antibody (MAb) |
en_ZA |
dc.subject |
Programmed cell death (PCD) |
en_ZA |
dc.subject |
T Helper 17 cells |
en_ZA |
dc.subject |
Immune-related adverse event (IRAE) |
en_ZA |
dc.title |
Immune dysregulation in cancer patients undergoing immune checkpoint inhibitor treatment and potential predictive strategies for future clinical practice |
en_ZA |
dc.type |
Article |
en_ZA |